Atea

Atea Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update

Retrieved on: 
Wednesday, February 28, 2024

BOSTON, Feb. 28, 2024 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) (Atea or Company), a clinical-stage biopharmaceutical company engaged in the discovery and development of oral antiviral therapeutics for serious viral diseases, today reported financial results for the fourth quarter and full year ended December 31, 2023 and provided a business update.

Key Points: 
  • Enrollment of the remainder of this study is ongoing with topline results anticipated in the second half of 2024,” continued Dr. Sommadossi.
  • Final results from the 60 patient lead-in cohort confirmed a 98% SVR4 rate across GT from 58 of 59 patients.
  • Final SVR12 results from all patients enrolled in the Phase 2 study are anticipated in the second half of 2024.
  • Cash, Cash Equivalents and Marketable Securities: $578.1 million at December 31, 2023 compared to $646.7 million at December 31, 2022.

Atea Pharmaceuticals Presents Promising Bemnifosbuvir and Ruzasvir Combination Data for the Treatment of Hepatitis C Virus at AASLD The Liver Meeting 2023

Retrieved on: 
Monday, November 13, 2023

BOSTON, Nov. 13, 2023 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) (Atea), a clinical-stage biopharmaceutical company engaged in the discovery and development of oral antiviral therapeutics for serious viral diseases, today announced the presentation of two posters supporting the combination of bemnifosbuvir, an oral nucleotide polymerase inhibitor, and ruzasvir, an oral NS5A inhibitor, as a potential treatment for Hepatitis C Virus (HCV) at the American Association for the Study of Liver Diseases’ (AASLD) The Liver Meeting 2023, being held from November 10-14, 2023 in Boston, MA.

Key Points: 
  • “Results from these two presented studies further support the potential use of these two drug candidates in combination as a novel treatment for HCV.
  • Phase 1 data demonstrate that coadministration of bemnifosbuvir and ruzasvir was well tolerated and not affected by food or concomitant dosing, indicating a low risk of drug-drug interactions,” said Jean-Pierre Sommadossi, PhD, Chief Executive Officer and Founder of Atea Pharmaceuticals.
  • These Phase 1 data support the continued clinical evaluation of these two potent drug candidates in combination for the treatment of HCV.
  • Results from an in vitro study demonstrate that the combination of bemnifosbuvir and ruzasvir has potent pan-genotypic antiviral activity against major HCV NS5A and NS5B RAVs and hard-to-treat sub-genotypes.

Atea Pharmaceuticals Reports Third Quarter 2023 Financial Results and Provides Business Update

Retrieved on: 
Wednesday, November 8, 2023

BOSTON, Nov. 08, 2023 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) (“Atea” or the “Company”), a clinical-stage biopharmaceutical company engaged in the discovery and development of oral antiviral therapeutics for serious viral diseases, today reported financial results for the third quarter ended September 30, 2023 and provided a business update.

Key Points: 
  • We’ve quickly completed enrollment of the   60-patient lead-in cohort and initial results are expected in early 2024," continued Dr. Sommadossi.
  • Currently, Atea anticipates providing an update after each of these interim analyses are completed with the first update expected to occur in the first quarter of 2024.
  • Cash, Cash Equivalents and Marketable Securities: $595.1 million at September 30, 2023 compared to $608.1 million at June 30, 2023.
  • Income Tax Expense: Income tax expense was $0.2 million for the quarter ended September 30, 2023 compared to a benefit of $3.8 million for the quarter ended September 30, 2022.

Atea Pharmaceuticals Announces Participation at Upcoming Investor Conferences

Retrieved on: 
Wednesday, November 8, 2023

BOSTON, Nov. 08, 2023 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) (“Atea”), a clinical-stage biopharmaceutical company engaged in the discovery and development of oral antiviral therapeutics for serious viral diseases, today announced that members of the Atea management team will participate in and present a business update at the following investor conferences in November.

Key Points: 
  • BOSTON, Nov. 08, 2023 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) (“Atea”), a clinical-stage biopharmaceutical company engaged in the discovery and development of oral antiviral therapeutics for serious viral diseases, today announced that members of the Atea management team will participate in and present a business update at the following investor conferences in November.
  • 6th Annual Evercore ISI HealthCONx Conference, Fireside Chat on Wednesday, November 29, 2023 at 3:00 p.m.
  • ET
    Live webcasts of the presentations will be available on the Company’s website at https://ir.ateapharma.com/ .
  • An archived webcast will be available on Atea Pharmaceuticals’ website for at least 90 days following the event.

Atea Pharmaceuticals to Present Bemnifosbuvir and Ruzasvir Data for the Treatment of Hepatitis C Virus at AASLD The Liver Meeting 2023

Retrieved on: 
Thursday, November 2, 2023

"We are very pleased to share with the scientific and clinical community supportive data for bemnifosbuvir and ruzasvir, highlighting the potential to use these two compounds together as a novel treatment for hepatitis C virus (HCV)," said Jean-Pierre Sommadossi, PhD, Chief Executive Officer and Founder of Atea Pharmaceuticals.

Key Points: 
  • "We are very pleased to share with the scientific and clinical community supportive data for bemnifosbuvir and ruzasvir, highlighting the potential to use these two compounds together as a novel treatment for hepatitis C virus (HCV)," said Jean-Pierre Sommadossi, PhD, Chief Executive Officer and Founder of Atea Pharmaceuticals.
  • "We are encouraged by the highly potent, pan-genotypic antiviral activity of these compounds, along with the favorable drug-drug interaction and safety profile observed to-date, which supports their use in combination.
  • Despite treatment options for HCV, there remains a large, underserved HCV patient population that continues to grow dramatically due to the opioid crisis, injection drug use and HCV reinfection."
  • Details for the presentations are as follows:

Atea Pharmaceuticals to Host Third Quarter 2023 Financial Results Conference Call on November 8, 2023

Retrieved on: 
Wednesday, November 1, 2023

ET to report financial results for the third quarter ended September 30, 2023, and to provide a business update.

Key Points: 
  • ET to report financial results for the third quarter ended September 30, 2023, and to provide a business update.
  • To access the live conference call, participants may register here .
  • The live audio webcast of the call will be available under "Events and Presentations" in the Investor Relations section of the Atea Pharmaceuticals website at ir.ateapharma.com .
  • An archive of the audio webcast will be available on Atea Pharmaceuticals’ website approximately two hours after the conference call and will remain available for at least 90 days following the event.

Atea Pharmaceuticals to Present at the Morgan Stanley 21st Annual Global Healthcare Conference

Retrieved on: 
Wednesday, September 6, 2023

BOSTON, Sept. 06, 2023 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) (“Atea”), a clinical-stage biopharmaceutical company engaged in the discovery and development of oral antiviral therapeutics for serious viral diseases, today announced that members of the Atea management team will participate in a fireside chat and present a business update at the Morgan Stanley 21st Annual Global Healthcare Conference on Wednesday, September 13, 2023 at 10:10 a.m.

Key Points: 
  • BOSTON, Sept. 06, 2023 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) (“Atea”), a clinical-stage biopharmaceutical company engaged in the discovery and development of oral antiviral therapeutics for serious viral diseases, today announced that members of the Atea management team will participate in a fireside chat and present a business update at the Morgan Stanley 21st Annual Global Healthcare Conference on Wednesday, September 13, 2023 at 10:10 a.m.
  • ET.
  • A live webcast of the presentation will be available here and on the Company’s website at https://ir.ateapharma.com/ .
  • An archived webcast will be available on Atea Pharmaceuticals’ website for at least 90 days following the event.

Atea Pharmaceuticals Reports Second Quarter 2023 Financial Results and Provides Business Update

Retrieved on: 
Tuesday, August 8, 2023

BOSTON, Aug. 08, 2023 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) (“Atea”), a clinical-stage biopharmaceutical company engaged in the discovery and development of oral antiviral therapeutics for serious viral diseases, today reported financial results for the second quarter ended June 30, 2023 and provided a business update.

Key Points: 
  • BOSTON, Aug. 08, 2023 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) (“Atea”), a clinical-stage biopharmaceutical company engaged in the discovery and development of oral antiviral therapeutics for serious viral diseases, today reported financial results for the second quarter ended June 30, 2023 and provided a business update.
  • During the second quarter of 2023, we began dosing HCV patients, and we look forward to reporting initial results from our lead-in cohort of approximately 60 patients by year-end 2023,” continued Dr. Sommadossi.
  • Interest Income and Other, Net: Interest income and other, net was $7.3 million for the quarter ended June 30, 2023 compared to $1.1 million for the quarter ended June 30, 2022.
  • Income Tax Expense: Income tax expense remained relatively consistent at $0.3 million for the quarter ended June 30, 2023 compared to $0.1 million for the quarter ended June 30, 2022.

Atea Pharmaceuticals to Host Second Quarter 2023 Financial Results Conference Call on August 8, 2023

Retrieved on: 
Tuesday, August 1, 2023

ET to report financial results for the second quarter ended June 30, 2023, and to provide a business update.

Key Points: 
  • ET to report financial results for the second quarter ended June 30, 2023, and to provide a business update.
  • To access the live conference call, participants may register here .
  • The live audio webcast of the call will be available under "Events and Presentations" in the Investor Relations section of the Atea Pharmaceuticals website at ir.ateapharma.com .
  • An archive of the audio webcast will be available on Atea Pharmaceuticals’ website approximately two hours after the conference call and will remain available for at least 90 days following the event.

Atea Pharmaceuticals Announces First Patient Dosed in Phase 2 Study for Treatment of Hepatitis C with Bemnifosbuvir and Ruzasvir Combination

Retrieved on: 
Thursday, June 15, 2023

BOSTON, June 15, 2023 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) (“Atea”), a clinical-stage biopharmaceutical company engaged in the discovery and development of oral antiviral therapeutics for serious viral diseases, today announced the dosing of the first patient in the Phase 2 bemnifosbuvir and ruzasvir combination study for the treatment of Hepatitis C Virus (HCV) infection.

Key Points: 
  • “The initiation of this Phase 2 combination study marks an important clinical milestone for Atea,” said Jean-Pierre Sommadossi, PhD, Chief Executive Officer and Founder of Atea Pharmaceuticals.
  • Patients will be administered 550 mg bemnifosbuvir in combination with 180 mg ruzasvir once-daily for eight weeks.
  • The primary endpoints of the study are safety and sustained virologic response (SVR) at Week 12 post-treatment.
  • Preliminary data from the 60 patient lead-in cohort are anticipated in the fourth quarter of 2023.